Medical Supplies

Sylveniusgatan 8A
75450 Uppsala
Sweden

Phone: (+46-18)570070
Fax: (+46-18)570080
http://www.mercodia.com
info@mercodia.se

Company Contacts
Department/ Name Address

Product Manager – Jeanette Nikus, PhD Tel: +46 18 57 00 97, Fax: +46 18 57 00 80, Mobile: +46 70 234 80 45
jeanette.nikus@mercodia.se

Company Figures
Number of employees 20-49
Sales volume < 1 Mio US $
Export content > 75%
Year of foundation 1991
Area of business Physiotherapy / Orthopaedic Technology / Occupational Therapy

Company Profile

About Mercodia
Mercodia develops, manufactures and markets high quality diagnostic immunoassay kits. We specialize in ELISA assays for clinical as well as research applications, notably within cardiovascular disease and diabetes. We offer assays applicable in both human and mammalian models.

Mercodia is committed to providing customers diagnostic kits of the highest quality, providing excellent performance and reproducibility in a convenient and easy to use format.

Mercodia provides a professional support system by collaborating with worldwide customers and institutions to develop new applications for existing products and new diagnostics for emerging markers.

Mercodia was founded in 1991 and is a management owned company. Mercodia supplies products to all major international markets from its facilities in Uppsala, Sweden. The product range is well accepted internationally and more than ninety percent of production is exported. Mercodia Inc, our US subsidiary, is based in Winston Salem, North Carolina and is involved in direct sales, shipping and support to our North American customers.

Our product philosophy is to offer customers diagnostic kits of the highest quality, providing excellent performance and reproducibility in a convenient and easy to use format. The use of monoclonal antibodies in the products ensures longterm reproducibility.

Mercodia provides a professional support system by collaborating with worldwide customers and institutuions to develop new applications for existing products and new diagnostics for emerging markers. We also offer tailor-made diagnostic tests developed from customer ideas according to customer specifications.

Please inquire about custom assay design to meet your specific needs.

Product Information
03.02.07 Immuno assay systems
Cardiovascular disease – Mercodia Apo(a) ELISA 28.04.2008

Article number: 10-1106-01 96 well

Lipoprotein (a)
Apolipoprotein(a), Apo(a), is a glycoprotein linked by disulphide bridges to apolipoprotein B in the lipoprotein(a) (Lp(a)) particle. Apo(a) is formed by three different structural domains. One of the domains, called kringle 4, is present in multiple copies, the number of which varies and is genetically determined, giving rise to different sizes of Apo(a) and consequently Lp(a). Depending on the method used, from six to 23 isoforms of apo(a) ranging from about 300 to 900 kD have been identified. Most individuals have one or two Apo(a) isoforms, although in some subjects no Apo(a) band can be detected when analysed in SDS-gel electrophoresis followed by immunoblotting.
Recently, much interest has been focused on Lp(a) since there is a lot of evidence that its circulating level represents an independent risk factor for coronary vascular disease. The Lp(a) level has been found to be an inherited risk factor for ischaemic heart disease. High Lp(a) levels have been demonstrated in familial hypercholesterolemia and its measurement may be clinically useful for risk prediction in these patients. Results have also been published on Lp(a) as a strong indicator for cerebrovascular disease.
Apo(a) is homologous to the protease zymogen plasminogen.
Lp(a) inhibits plasminogen activation and recent studies have shown that Apo(a) and Lp(a) compete with plasminogen for binding to the plasminogen receipt. These properties of Apo(a) may explain the association of high Lp(a) concentrations with myocardial infarction.

FEATURES • High Precision
• No crossreactivity with plasminogen or Apo B
• Wide measuring range
• Can measure lipemic, turbid samples or samples that have been frozen

Cardiovascular disease – Oxidized LDL ELISA 28.04.2008

Article number: 10-1143-01 96 well

Circulating oxidized LDL
Atherosclerosis is a chronic inflammatorydisease, not a degenerative disease, as previously believed. In this regard, oxidized LDL has been implicated as a potent atherogenic protein primarily found in atherosclerotic lesions of the coronaryartery wall. Oxidized LDL is not found in normal arteries. Native (nonoxidized)LDL, by itself, is not atherogenic. It must be oxidativelymodified to become atherogenic. Oxidized LDL is directly involved in the initiation and progression of the atherosclerotic disease process ? from the early-stage conversion of monocytes/ macrophages into lipid-laden foam cells, to the late-stage development of coronary artery stenosis, plaque instability, plaque rupture, coronary thrombosis, and myocardial infarction.

Coronary artery disease patients generally show elevatedblood levels of oxidized LDL prior to treatment. These high levels indicate that the atherosclerotic disease process (atherogenesis) in the artery wall is accelerated.

Evidence relating oxidized LDL to accelerated atherosclerosis and coronary artery disease is stronger now than ever before. Cardiologists increasingly accept the measurement of circulating oxidized LDL as a useful diagnostic indicator for better therapeutic management of patients with coronary artery disease.

FEATURES • Measuring circulating levels of Oxidized Low Density Lipoprotein
• Monoclonal
• Results within 3.5 h
• Breakable strips

Diabetes Mammalian 28.04.2008

Mercodia Bovine Insulin ELISA
An enzyme immunoassay for quantification of insulin

Article number: 10-1131-01 96 well

Bovine Insulin
Insulin is the principal hormone responsible for the control of glucose metabolism.
It is synthesised in the ß-cells of the islets of Langerhans as the precursor, proinsulin,
which is processed to form C-peptide and insulin. Secretion of insulin is mainly
controlled by plasma glucose concentration, and the hormone has a number of
important metabolic actions. Its principal function is to control the uptake and
utilisation of glucose in peripheral tissue via the glucose transporter. This and other hypoglycaemic activities, such as the inhibition of hepatic gluconeogenesis and glycogenolysis are counteracted by the hyperglycaemic hormones including
glucagon, epinephrine (adrenaline), growth hormone and cortisol.

Mercodia Bovine Insulin kit is an easy way for determination of insulin levels in serum, plasma and other biological media.

Mercodia Mouse Insulin ELISA 96 well
An enzyme immunoassay for quantification of insulin

Article number: 10-1149-01 96 well

Mouse Insulin
Insulin is the principal hormone responsible for the control of glucose metabolism.
It is synthesised in the ß-cells of the islets of Langerhans as the precursor, proinsulin,
which is processed to form C-peptide and insulin. Secretion of insulin is mainly
controlled by plasma glucose concentration, and the hormone has a number of
important metabolic actions. Its principal function is to control the uptake and
utilisation of glucose in peripheral tissue via the glucose transporter. This and other
hypoglycaemic activities, such as the inhibition of hepatic gluconeogenesis and
glycogenolysis are counteracted by the hyperglycaemic hormones including
glucagon, epinephrine (adrenaline), growth hormone and cortisol.
Mercodia Mouse Insulin kit is a easy way for determination of mouse
insulin in serum, plasma and other biological media.

Obesity 08.10.2007

Adiponectin ELISA
A high quality enzyme immunoassay for the quantification of human adiponectin in serum or plasma.

Article number: 10-1193-01 96 wells

03.02.07.06 Enzyme immunoassay (EIA, ELISA, EMIT)
Cardiovascular disease – Mercodia MPO ELISA 28.04.2008

Article number: 10-1176-01 96 wells

Myeloperoxidase
Myeloperoxidase (MPO), an iron containing glycoprotein, is a covalently bounded tetrameric complex with a molecular weight of 150 kDa. It is composed of two glycosylated alfa chains of MW 59-64 kDa and two unglycosylated beta chains of MW 14 kDa. MPO is found in abundance in the primary azurophilic granules of neutrophils and is present in monocytes.

In response to microbial invasion, MPO is released from the cytoplasmic granules of neutrophilis into the phagasome and extracellular space, catalysing the conversion of hydrogen peroxide and chloride ions (Cl) into hypochlorous acid, a potent oxidant agent.

Myeloperoxidase traditionaly is used as a marker of airway inflammation caused by asthma or environmental irritants. It is also believed that MPO participates in different stages of atherogenesis and has a potential role in the promotion of atherosclerosis. Association between elevated MPO levels in serum and cardiovascular disease (CAD) supports an important role for MPO as an inflammatory marker in CAD, making it possible to identify patients at risk for cardiac events in the absence of mycardial necrosis.

FEATURES Two MPO specific monoclonal antibodies
Sandwich ELISA
Liquid calibrrators ready for use
Incubation times: 1 h + 1h + 15 min
Sample volume: 25 µl
Test reange: 3-300 µg/l

Cardiovascular disease – Oxidized LDL Competitive ELISA 28.04.2008

Article number: 10-1158-01 96 wells

Circulating oxidized LDL
Atherosclerosis is a chronic inflammatory disease, not a degenerative disease, as previously believed. In this regard, oxidized LDL has been implicated as a potent atherogenic protein primarily found in atherosclerotic lesions of the coronaryartery wall. Oxidized LDL is not found in normal arteries. Native (non oxidized)LDL, by itself, is not atherogenic. It must be oxidatively modified to become atherogenic. Oxidized LDL is directly involved in the initiation and progression of the atherosclerotic disease process from the early-stage conversion of monocytes/ macrophages into lipid-laden foam cells, to the late-stage development of coronary artery stenosis, plaque instability, plaque rupture, coronary thrombosis, and myocardial infarction.

Coronary artery disease patients generally show elevatedblood levels of oxidized LDL prior to treatment. These high levels indicate that the atherosclerotic disease process (atherogenesis) in the artery wall is accelerated.

Evidence relating oxidized LDL to accelerated atherosclerosis and coronary artery disease is stronger now than ever before. Cardiologists increasingly accept the measurement of circulating oxidized LDL as a useful diagnostic indicator for better therapeutic management of patients with coronary artery disease.

FEATURES • Measuring circulating levels of Oxidized Low Density Lipoprotein
• Monoclonal
• Results within 3.5 h
• Breakable strips

Controls 28.04.2008

Mercodia Diabetes-antigen Control Human, H and L

Article number: 10-1164-01 2X0.5ml

Mercodia Diabetes-antigen Control is designed to be used as a
two-level control for human insulin, C-peptide and proinsulin.
It is manufactured from human serum and human insulin, C-peptide and proinsulin.

Mercodia Insulin Control Mammalian/(Low, High)
Mercodia Insuiln Control is designed to be used as a two-level control for Mercodia Rat,
Mouse, Porcine, Bovine, and Sheep Insulin ELISA kits. It is manufactured from human serum and insulin.

Article number: 10-1135-01 2x 0.5ml

Oxidized LDL Control Kit / human

Article number: 10-1165-01 2×0.5ml

Diabetes Human 28.04.2008

Mercodia C-peptide ELISA
A specific enzyme immunoassay for quantification of human C-peptide

Article number: 10-1136-01 96 well

C-peptide
Qualitative and quantitative evaluation of pancreatic ß-cell function is not only of use in the pre- and post-diagnostic study of the natural history of diabetes mellitus, but is also relevant in clinical practice as a guide to the correct choice of treatment. Peripheral insulin levels cannot be used to assess ß-cell function because of a large and variable uptake from the portal circulation into the liver, and because insulin assays cannot distinguish endogenous from exogenous insulin.

Within the pancreatic ß-cell, proinsulin is cleaved into one molecule of C-peptide and one molecule of insulin. C-peptide is subsequently released into the circulation at concentrations equimolar to those of insulin. In contrast to insulin, C-peptide is only minimally extracted by the liver. Peripheral C-peptide concentrations therefore reflect the secretion of ß-cells more accurately than insulin.

Urinary C-peptide excretion is correlated with integrated plasma C-peptide levels but the extraction is highly variable between and within individuals and is, therefore, an imprecise measure of ß-cell function.